INTRODUCTION
Angiotensin I converting enzyme 1 (DCP1, EC 3.4.15.1) (ACE) is a zinc metallopeptidase which plays an important role in blood pressure regulation by cleaving the inactive decapeptide angiotensin I to angiotensin II, a potent vasopressor octapeptide. It also inactivates bradykinin, a potent vasodilator peptide (1) . There are two ACE isoforms transcribed from a single ACE gene by two alternate promoters (2) . Somatic ACE (170 kDa) is synthesized by vascular endothelial cells, and several types of epithelial cells whereas testis ACE (110 kDa) is expressed exclusively by male germinal cells (3, 4) .
Somatic ACE consists of two homologous catalytic domains, a juxtamembrane stalk region, a hydrophobic transmembrane domain of 17 amino acids, and a 30 residues C-terminal cytosolic domain (5) . Thus ACE is primarily an integral membrane protein anchored to the plasma membrane by its carboxyl-terminal segment. But the membrane-bound enzyme can be fully solubilized in vitro by detergents or limited proteolytic cleavage (6) . In vivo, a soluble form of the enzyme exists in plasma and other body fluids (7) . Plasma ACE is known to be strongly modulated by a common polymorphism in linkage disequilibrium with an insertion/deletion polymorphism (8) . Although this quantitative trait locus was localized on the ACE gene itself (9) , the functional variant has not yet been identified.
Human plasma ACE is derived from endothelial cells by post-translational cleavage by a Several membrane-anchored proteins are solubilized by limited proteolysis with release of their extracellular domains. This common phenomenon, also referred to as "shedding" dysplays typical characteristics such as induction by phorbol esters, calcium ionophores, and unidentified serum factor ; inhibition of the shedding protease by hydroxamate-based metalloprotease inhibitors ; localization of the shedding event at the cell surface and structural requirements of the juxtamembrane stalk that determine cleavage efficiency (10) (11) (12) . Cleavage secretion of ACE is topologically constrained to an accessible stalk region of at least 11 residues in length, and requires a minimum distance of three residues from the proximal extracellular domain and eight residues from the membrane (10) . Furthermore, mutational analysis of the stalk region has shown that conservation of the amino acid sequence was not essential for shedding, even though the secretase seems to have a weak preference for cleavage after Arg or Lys residues by guest on January 8, 2018 http://www.jbc.org/ Downloaded from 4 (10, 13, 14) . Thus, the critical parameter, for cleavage efficiency seems to be the conformation of the stalk more than the amino acid sequence. In addition, experiments using the homologous stalk region of CD4, which is not cleaved, to construct a chimeric ACE, revealed that the distal extracellular domain of ACE also has a prominent role for determining the cleavage (14) .
Here we report the identification of a Pro!Leu 1199 mutation found associated with high plasma ACE levels in 3 unrelated Dutch individuals. In vitro study of this mutation was performed and effects of this mutation on the solubilization process of ACE were investigated.
We present experimental results showing that this single amino acid change in the stalk region is responsible for an enhancement of the cleavage and secretion of ACE, in an ACE-secretase activity dependent way. An hypothesis implicating a modification of the ACE structure due to the point mutation, and leading to a better accessibility for ACE secretase, is proposed.
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Site-directed mutagenesis
A single Pro (CCG) to Leu (CTG) mutation at position of amino acid 1199 was introduced into pACE-WT (or peACE), an expression vector containing the full length somatic ACE cDNA controlled by the SV 40 early promoter (15) . An oligonucleotide-directed mutagenesis system (Quickchange site-directed mutagenesis kit, Stratagene) was used according to the manufacturer's recommendation. The following oligonucleotides containing the desired mutation were used : 5'-GCAGTACAACTGGACG CTG AACTCCGCTCGC-3' (sense) ; 5'-GCGAGCGGAGTT CAG CGTCCAGTTGTACTGC-3' (antisense). Mutant cDNAs were screened by DNA sequencing. One mutant containing the desired mutation was selected and designed as pACE leu1199 . The entire cDNA fragment of this construct was sequenced to ensure that no other mutations occurred. The same protocol was used to introduce the Pro!Leu 1199 mutation into plasmid pACE-CF containing the coding sequence for the signal peptide, the Cterminal domain and the transmembrane domain of human endothelial ACE (16). The mutant containing the desired mutation was designed as pACE-CF leu1199 .
Transient expression of pACE-WT, pACE leu1199, pACE-CF and pACE-CF leu1199 pACE-WT, pACE leu1199 , pACE-CF and pACE-CF leu1199 were expressed in COS-7 cells.
Transient transfections were performed by using polyethyleneimine suspension in a commercially available solution (EXGEN 500). COS-7 cells (250×10 3 /well) were plated on a 6
well plate and incubated 24 h in DMEM medium supplemented by 10% heat inactivated fetal calf serum, 2 mM L-glutamine, 100 units/ml penicillin-streptomycin, then treated with a mix containing 2 µg of plasmid, 4 µl of EXGEN 500 and NaCl (150 mM) in a final volume of 100 µl. The same protocol was used to express pACE-WT and pACE leu1199 in HMEC-1 (human microdermal endothelial cells transfected and immortalized with a pBR-322-based plasmid containing the coding region for the SV 40 A gene product, large T antigen) (17) except that :
they were grown in MCDB-131 medium supplemented by 20% heat inactivated fetal calf serum, 7 hydrocortisone and that 6 µl of EXGEN 500 were used for transfection. Cells were incubated over-night with the transfection mix.
Expression of pACE leu1199 in CHO cells pACE leu1199 was introduced by cotransfection with neomycin resistance plasmid pSV2neo into CHO cells. CHO cells (1×10 6 ) were plated on 10 cm 2 petri dish, incubated 24 h, then treated with a mix containing 2.95 µg of pACE leu1199 , 500 ng of pSV2neo, 6 µl of EXGEN 500 and NaCl (150 mM) in a final volume of 100 µl. The transfected cells were grown in DMEM medium supplemented with 10% heat inactivated fetal calf serum, 2 mM L-glutamine, 100 units/ml penicillin-streptomycin and 750 µg/ml geneticin. Single colonies of primary G418-resistant transformants were assayed for the expression of pACE leu1199 by western-blot analysis and enzymatic assays (see below). Cell lines expressing pACE leu1199 were selected and purified by subcloning using limiting dilution. Establishment of a CHO cell line expressing pACE-WT has been previously described (15) .
Metabolic labelling and Immunoprecipitation
Wild-type and mutant ACE CHO cell lines with similar cellular contents of ACE activity were seeded in 60-mm dishes at a density of 2×10 6 cells/dish and grown to confluency. Metabolic labelling and immunoprecipitation were performed as previously described (18) , except that immunoprecipitation was performed using antiserum HKE, obtained from sheeps immunized against pure human kidney ACE, and protein G-Sepharose (Sigma, L'Isle D'abeau Chesnes, France). Proteins were resolved by 7.5% SDS-polyacrylamide gel electrophoresis and revealed by autoradiography.
Preparation of subcellular fractions
CHO cells expressing wild-type ACE and ACE leu1199 were scrapped and suspended in buffer A containing 50 mM HEPES pH 7.5, 0.25 M sucrose and 5 mM MgCl 2 . All steps were performed at 4 °C. The cell suspension was homogenized using a glass-Teflon homogenizer for 8 centrifuged at 10,000 g for 10 min. The pellet was solubilized in CHAPS (8 mM) and conserved as lysosomal fraction. The supernatant was centrifuged again at 105,000 g for 1 h.
The sedimented membranes were washed with buffer A and solubilized in CHAPS (8 mM), the supernatant was conserved as cytosolic fraction.
Enzymatic characterization
Cells were scrapped and washed with phosphate-buffered saline (PBS), then centrifuged at 1,200 g for 10 min. The pellet was dissolved in CHAPS (8 mM). After stirring for 12h to solubilize the membrane bound ACE, the suspension was centrifuged at 12,000 g for 10 min
and the supernatant was used for enzymatic assays.
Secreted ACE was obtained from the culture medium of transfected cells grown in serum free medium.
All enzymatic studies were performed using p-benzoyl-L-glycyl-L-histidyl-L-leucine (Hip-HisLeu, Bachem, Switzerland) as substrate. The detection and quantification of hippuric acid released from the Hip-His-Leu were performed by HPLC as previously described (15) . Kinetic parameters for the hydrolysis of Hip-His-Leu were determined from Michaelis-Menten plots using ENZFITTER software. All enzymatic studies were performed under initial rate conditions.
Western-blot Analysis
Two different rabbit antisera were used to characterize expressed forms of ACE : Antisera 3 and 4 (18) which were raised against synthetic peptides corresponding to sequences of the carboxylterminal ACE ( fig. 1 Computer assisted structural analysis
Multiple alignment of domain 1 (N-terminal domain) and domain 2 (C-terminal domain) of several ACE orthologs was performed using CLUSTALW program (19) . Sequences data used are available at the Swiss-Prot data base under accession number : P12821, P09470, Q10751.
Hydrophobic cluster analysis (HCA), a 2D structure prediction method, based on the detection and comparison of the structural segments constituting the hydrophobic core of globular protein has been described elsewhere (20, 21) . ACE sequences were submitted to HCA analysis and domain 1 and domain 2 of ACE orthologs were aligned according to hydrophobic clusters determined by HCA plots.
Optimal alignment was performed using combined data from CLUSTALW and HCA analysis.
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RESULTS

Biochemical parameters
Three unrelated subjects having marked increase of plasma ACE levels were identified through a screening of patients referred to a general hospital (55. In order to elucidate the mechanism by which this mutation was responsible for the high plasma ACE levels observed in these individuals, an in vitro study using site directed mutagenesis was undertaken.
Expression of wild-type ACE and ACE leu1199 in COS-7 and HMEC-1 cells
The expression plasmid pACE-WT (or peACE) was used to direct the synthesis of wildtype ACE (16). The expression plasmid pACE leu1199 is identical to pACE-WT except for a single Pro (CCG) to Leu (CTG) mutation at position 1199 of the coding sequence of somatic ACE, and was used to direct the synthesis of ACE leu1199 .
The kinetic parameters for Hip-His-Leu hydrolysis of the wild-type ACE and of the ACE leu1199 , calculated from Michaelis-Menten plot, were not significantly different ( fig 2) . The K m and the V max values of the ACE leu1199 were similar to that of the wild-type ACE (3.33 ± 0.11 mM vs 2.51 ± 0.12 mM and 0.35 ± 0.007 nmol/ml/min -1 vs 0.34 ± 0.008 nmol/ml/min -1 ).
with Hip-His-Leu substrate by HPLC. No significant difference was observed in levels of cellassociated ACE between wild-type form and ACE leu1199 all along the time course study (fig 3   A ). In contrast, levels of soluble ACE leu1199 activity was higher than wild-type ACE suggesting that the rate of release was enhanced (fig 3 C ). The percentage of solubilization which was defined as the ratio of the enzymatic activity in the medium to the total enzymatic activity (medium + cells) was in average 1.5 fold higher for ACE leu1199 , as compared to wild-type ACE in COS-7 cells with a maximum difference of 2.5 fold at 24 h (fig 3 E).
We also investigated the rate of secretion of ACE leu1199 in HMEC-1, an endothelial cell line which does not express ACE, because endothelium is a major site of expression of ACE in vivo and the source of plasma ACE (fig 3 B , D, F). Higher levels of soluble ACE leu1199 activity were observed, as compared to wild-type ACE, and lower cell associated ACE activity was observed.
The rate of solubilization was in average 2.5 fold higher for ACE leu1199 compared to wild-type form.
These data showed that a leucine in position 1199 instead of a proline in ACE protein leads to an enhancement of cleavage and secretion of ACE. Thus, both in an endothelial cell type and a nonendothelial cell type, differences between wild-type ACE and ACE leu1199 release observed in vitro are consistent with the plasma ACE increase observed in subjects bearing this mutation.
Biosynthesis and secretion of metabolically labelled wild-type ACE and ACE leu1199
CHO cells stably transfected with the expression plasmid pACE-WT or pACE leu1199 were used to investigate the role of the Pro!Leu 1199 mutation on ACE secretion. Cells were labeled for 30 min with [ in contrast with wild-type ACE which was difficult to detect in the medium even after 16 h of chase.
The metabolic labelling results were consistent with the kinetic experiments based on ACE activity, indicating that ACE leu1199 was released more efficiently from the cell surface than wildtype ACE.
Subcellular localization of ACE leu1199
To test whether the Pro→Leu 1199 mutation influences the intracellular trafficking of ACE, distribution of ACE was determined in various compartments of CHO cells stably transfected with either wild-type ACE or ACE leu1199 grown for 3 or 24 h in serum-free medium.
Medium was then collected and lysosomal, cytosolic and membranous compartments were separated by successive centrifugations. ACE activity was measured in each fraction and expressed as percent of total ACE activity ( fig 5) . We controlled that total ACE activity was equivalent for wild-type ACE and ACE leu1199 .
ACE activity measured in the cytosol for wild type ACE and ACE leu1199 was very low indicating that these proteins are rapidly addressed to the membrane. A higher proportion of total ACE (38.6 ± 8.5 % for wild-type ACE and 24.9 ± 9.7 % for ACE leu1199 at 3 h) was detected in lysosomal fraction. At 3 h (fig 5 A) only 6 % of total ACE leu1199 was detected in membranous compartment whereas high level of ACE leu1199 (34 % of total ACE) was observed in the medium. At the same time, wild-type ACE levels were similar in membranous compartment and medium (17 % and 16 % of total ACE respectively). This difference between ACE leu1199 and wild-type ACE was more pronounced at 24 h (fig 5 B) .
Immunological characterization of membrane bound and soluble ACE leu1199
In order to map the cleavage site of ACE leu1199 , western-blot analyses using specific antibodies were performed ( fig 6) . Antiserum 3 raised against sequences from the C-terminal side of the Arg-1203/Ser-1204 cleavage site (22) and antiserum 4 directed against a synthetic peptide located at the N-terminal side of this cleavage site (fig 1) .
CHO cells stably transfected with either wild-type ACE and ACE leu1199 were grown to subconfluence and then incubated in serum-free medium for 48 h. Medium and CHAPSsolubilized cell lysates were analyzed on SDS-PAGE gel followed by western-blotting. 
Role of the N-terminal domain : Expression of ACE-CF leu1199 in COS-7 cells and effect of PMA on secretion
The possible effect of the amino-terminal domain on ACE leu1199 solubilization was investigated using expression plasmid pACE-CF containing full length somatic ACE cDNA except the coding sequence for the N-terminal domain (16). pACE-CF and pACE-CF leu1199 were transiently expressed in COS-7 cells (fig 8 A) . At 6 h near 50% of ACE-CF was solubilized in medium whereas at the same time only 20% of wild-type somatic ACE was secreted (compared fig 3 E and fig 8 A) , confirming the lower solubilization of the two domains containing enzyme.
14 We observed a significantly higher rate of release for ACE-CF leu1199 as compared to ACE-CF after 1 h (31% vs 7% respectively). The percentage of solubilization was in average 1.8 fold higher for ACE-CF leu1199 as compared to ACE-CF in COS-7 cells.
We also investigated the effect of PMA on ACE-CF and ACE-CF leu1199 solubilization. (fig 8 B) .
PMA enhanced the rate of solubilization of ACE-CF and ACE-CF leu1199 . After 15 min, 14% of ACE-CF and 62% of ACE-CF leu1199 were secreted out of PMA-treated cells whereas in untreated cells only 5% of ACE-CF and 20% of ACE-CF leu1199 were solubilized at the same time. PMA effect was more pronounced on ACE-CF leu1199 solubilization in very early times of kinetics before becoming similar between ACE-CF and ACE-CF leu1199 after 2 h.
Structural analysis
The HCA plots of domain 1 (N-terminal domain) and domain 2 (C-terminal domain) of several ACE orthologs were compared in order to produce an optimal alignment. 
DISCUSSION
We report a mutation of the ACE gene which was found in 3 apparently healthy unrelated individuals from the same ethnic origin and selected for having very high plasma ACE levels. Pathological causes of high plasma levels could be eliminated in these individuals.
Moreover, the genetic origin of the very high plasma ACE levels was supported by the Mendelian transmission of the trait in the families of these subjects (Kramers et al. submitted).
Familial elevations of plasma ACE levels were already described in Japan and Italy but their molecular bases have not been elucidated (23, 24) .
In view of its large effect, the genetic increase of plasma ACE levels which was observed in these subjects could not be attributed to the common polymorphism of the ACE gene, which explains 30% of plasma ACE variance in the Caucasian population, and which is in linkage disequilibrium with an insertion/deletion polymorphism located within intron 16 of the ACE gene (8, 25) .
The complete sequencing of the exons of the ACE gene was performed in order to detect a mutation specific to the 3 individuals. DNA sequencing revealed a mutation in exon 25 leading to a Pro!Leu mutation in position 1199 of the somatic form of ACE. This mutation was not found in a large series of Caucasian subjects and no other mutation was found in the coding sequence of the 3 selected subjects.
Because the Pro!Leu 1199 mutation was located in the stalk region, which links the transmembrane domain to the first extracellular domain, near the identified cleavage site (22) , it was considered as a good candidate and its functional effect was further investigated. We introduced the Pro!Leu 1199 mutation into a somatic ACE expression vector and we observed, as expected, no difference in enzymatic properties between the ACE leu1199 and the wild-type ACE. The cleavage secretion process was therefore the most likely to be affected by the mutation. We investigated the release rate in two different cell lines, the COS-7 cells already used in previous studies, and the HMEC-1, an endothelial dermal microvessel cell line which does not synthesize ACE. In both cell lines an increased secretion rate of ACE leu1199 was observed, as compared to wild-type ACE. in ACE concentration of the medium, indicating that a global increase of ACE production cannot explain the phenomenon observed. It is remarkable that an important part of total ACE is retrieved in the lysosomal fraction, indicating that a high proportion of both mutated and wildtype ACE is degraded before it is addressed to the membrane or that it is recycled from the membrane.
Two antibodies, raised against peptides flanking the cleavage site determined for both human testicular and somatic ACE (26) , were used to determine whether ACE leu1199 was cleaved at the same location as the wild-type enzyme. Indeed, ACE leu1199 is cleaved between amino acid 1162 and 1214, a result consistent with the cleavage site determined for the in vitro expressed wildtype somatic and testicular enzymes, and for the seminal plasma ACE (26) . Thus, our results do not favor the hypothesis of another cleavage site created by the mutation but suggest a more active cleavage rate at the major site. However we cannot exclude that a small fraction of secreted ACE, not detected with antiserum 4, is cleaved at a secondary cleavage site, such as the one described between Arg-1137 and Leu 1138 for human plasma ACE (13) .
The cleavage secretion of ACE is an enzymatic process which can be modulated by pharmacological agents. A hydroxamic acid-based inhibitor of metalloproteases, compound 3, was shown to block very effectively the cleavage-processing activity of testicular ACE in a mouse epithelial cell line (ACE 89) stably transfected with the rabbit testicular ACE (27). Our data show that compound 3 completely abolished ACE leu1199 secretion as well as wild-type ACE during a prolonged period of time (12 hours), after which a progressive degradation of the inhibitor likely enables secretion to rise again. This clearly indicates that the increased cleavagesecretion process observed for ACE leu1199 results from the similar enzymatic process to the wildtype, and not from cleavage due to another type of enzyme or from a non specific leakage from the membrane.
Phorbol esters, which activate PKC, were shown to enhance the rate of ACE cleavagesecretion, with a marked difference between the somatic and testicular isoforms, the latter being by guest on January 8, 2018
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The cleavage secretion of somatic ACE is lower compared to testicular ACE and it has been proposed that the N terminal domain could have an inhibitory effect on its secretion. Since both the basal and phorbol ester induced cleavage secretion of ACE leu1199 resembled what is observed for the testicular isoform of ACE, we investigated the hypothesis that the mutation could suppress an effect of the N-domain on solubilization. This was achieved by introducing the mutation in an ACE expression vector lacking the N-domain of ACE (pACE-CF) (16). At the basal level, secretion of ACE-CF leu1199 was increased four fold as compared to the wild type ACE-CF in COS-7 cells. After treatment with PMA, an early four fold increase of ACE-CF leu1199 secretion rate was observed as compared to the wild type ACE-CF. Two kinds of arguments drawn from our results indicate that the mutation is not acting through the suppression of an inhibitory effect of the N-domain on the secretion rate. Firstly, cleavagesecretion of somatic ACE leu1199 is lower compared to C-domain ACE leu1199 . Secondly, the effect of the Pro→Leu 1199 mutation on secretion increase is also observed with the recombinant ACE molecule lacking the N-domain.
It was recently shown that, in the ACE89 cell line, testicular ACE can make a complex with PKC subunits, and that this complex dissociates in the presence of phorbol ester (28) . A subsequent enhanced effect of ACE secretase was proposed to explain the phorbol ester induced cleavage-secretion. In the cases of both somatic and C-domain ACE (ACE-CF) with the Pro!Leu 1199 mutation, the preservation of a higher solubilization rate under PMA indicates that the increase in speed of shedding induced by the putative PMA-induced complex dissociation can be still enhanced by a change in conformation.
Because no data is available about the ACE 3D-structure, we performed multiple alignment deduced from HCA plots of the N-terminal and the C-terminal domains of several ACE orthologs in order to predict secondary structures around proline 1199. It is remarkable that proline 1199 is highly conserved among ACE family sequences. Furthermore, this amino acid is the last common residue of the two domains preceding a loop specific of the C-terminal Thus, even though it was shown that the cleavage-secretion process is not constrained by a specific amino acid sequence but much more by topological parameters (10), we show here that an amino acid sequence important for the conformational state of the juxtamembrane stalk region is critical for ACE release. More investigation in the structural conformation of the stalk region would provide interesting data for the study of the regulated shedding of ACE and other shedded membrane associated proteins.
The elucidation of the molecular basis of a QTL affecting the plasma concentration of ACE has implications which go beyond the ACE gene itself. Firstly, it illustrates that a QTL is not necessarily acting by modifying the expression level of the gene affected by the QTL, but that conformational change can modify its secretion rate and, hence, its concentration in a particular biological fluid where it can be measured in clinical practice. Secondly, it shows that the plasma concentration is a biological phenotype which can be of limited value since it does not necessarily reflect the level of expression at the cellular level. In the case described here, the membranous concentration of ACE is even slightly decreased and the high plasma concentration is not associated with any detectable pathological effect. In contrast, it has been shown that the above mentioned common polymorphism of ACE also affects the cellular level of the enzyme, where it can cause potential deleterious effects (29) 
